Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm
JAMA Network Open · 26.06.2026 · 9 (6) · e2617587
DOI: 10.1001/jamanetworkopen.2026.17587 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JAMA Network Open, online erschienen am 26.06.2026. Verfasst von Charlotte A Leseman und 14 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: CA-19-9 Antigen, Carcinoma, Pancreatic Ductal, Pancreatic Intraductal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Current guidelines recommend routine assessment of serum carbohydrate antigen 19.9 (CA19.9) at diagnosis and during follow-up of patients with intraductal papillary mucinous neoplasm (IPMN) to detect high-grade dysplasia (HGD) and invasive carcinoma (IC). Guidelines consider an elevated serum CA19.9 level (≥37 U/mL) a worrisome feature and a relative indication for surgery.
Objective
To evaluate the diagnostic accuracy of CA19.9 for identifying patients with IPMN at high risk of HGD and IC. Data Sources PubMed, Embase (Ovid), and Web of Science databases (inception to March 1, 2025). Study Selection Studies reporting on diagnostic accuracy of CA19.9 (cut-off 37 U/mL) in patients with resected IPMN. Data Extraction and Synthesis Data extraction was completed by 3 reviewers (March to December 2025). Risk of bias was assessed using the QUADAS-2 tool and evidence certainty with Grading of Recommendations Assessment, Development and Evaluation. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses of Diagnostic Test Accuracy Studies reporting guidelines and the Cochrane Diagnostic Test Accuracy protocol were applied for overall conduct. A random-effects meta-analysis was conducted in December 2025 to obtain a pooled estimate of diagnostic accuracy. Main pancreatic duct involvement and rate of HGD or IC were assessed using meta-regression. Summary receiver operating characteristics curves were generated. The area under the curve (AUC) was calculated as overall test performance. Main Outcomes and Measures Diagnostic accuracy of serum CA19.9 (≥37 U/mL), reported as pooled sensitivity, specificity, positive likelihood ratio (PLR) and negative likelihood ratios (NLR), diagnostic odds ratio (DOR), and AUC and their 95% CIs. Pathology was considered as reference standard.
Results
Overall, 24 studies assessing 5281 patients with IPMN were included. Mean age was 64.7 (95% CI, 62.24-67.10) years, and 2919 patients (55%) were male. Serum CA19.9 data were available for 4653 patients (88.1%), with 966 patients (20.8%) showing elevated levels. Pooled estimates of diagnostic accuracy for HGD or IC (present in 1939 patients [41.7%]) demonstrated sensitivity of 0.35 (95% CI, 0.29-0.43), specificity of 0.90 (95% CI, 0.87-0.92), PLR of 3.37 (95% CI, 2.56-4.44), NLR of 0.72 (95% CI, 0.65-0.80), DOR of 4.67 (95% CI, 3.26-6.70), and AUC of 0.78 (95% CI, 0.74-0.82).
Conclusions
And Relevance In this systematic review and meta-analysis, CA19.9 with the current cutoff (37 U/mL) demonstrated poor performance in excluding HGD or IC and only modest value for ruling in IC. These findings suggest CA19.9 should not be used as a standalone or screening test, while its limited rule-in value may aid decision-making in patients with moderate pretest probability. Future studies should investigate whether different cutoffs and dynamic trends could improve diagnostic accuracy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands.
- Cancer Center Amsterdam, Amsterdam, the Netherlands.
- General Surgery Unit, ASST Brianza-Vimercate Hospital, Vimercate, Italy.
- ASST Grande Ospedale Metropolitano Niguarda, Acute Care and Trauma Surgery, Milan, Italy.
- Division of Pathology, Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden.
- Medical Unit Cell Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital, Stockholm, Sweden.
Zitieren
APA
Leseman, C. A., Bonomi, A. M., Schuitema, J., Granieri, S., Sällberg Chen, M., Maker, A. V., Ateeb, Z., Wood, L. D., Voermans, R. P., Marchegiani, G., Del Chiaro, M., Ket, J. C. F., Lennon, A. M., Besselink, M. G., & Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group (2026). Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm. JAMA Network Open, 9(6), e2617587. https://doi.org/10.1001/jamanetworkopen.2026.17587
Vancouver
Leseman CA, Bonomi AM, Schuitema J, Granieri S, Sällberg Chen M, Maker AV, et al. Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm. JAMA Network Open. 2026;9(6):e2617587. doi:10.1001/jamanetworkopen.2026.17587
BibTeX
@article{Leseman2026,
author = {Leseman, Charlotte A and Bonomi, Alessandro M and Schuitema, Job and Granieri, Stefano and Sällberg Chen, Margaret and Maker, Ajay V and Ateeb, Zeeshan and Wood, Laura D and Voermans, Rogier P and Marchegiani, Giovanni and Del Chiaro, Marco and Ket, Johannes C F and Lennon, Anne Marie and Besselink, Marc G and Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group, Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group},
title = {Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary Mucinous Neoplasm},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {6},
pages = {e2617587},
doi = {10.1001/jamanetworkopen.2026.17587}
}
EUVIMED